

FOR ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
FOR ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS

WATCH
ME



Cosentyx®
(secukinumab)



MOVE AND
FEEL BETTER

This brochure contains photos of **actual patients** who have taken COSENTYX® and have been compensated for their time. Individual results may vary.

INDICATIONS

COSENTYX® (secukinumab) is a prescription medicine used to treat:

- people 6 years of age and older with moderate to severe plaque psoriasis (PsO) that involves large areas or many areas of the body, and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light alone or with systemic therapy)
- people 2 years of age and older with active psoriatic arthritis (PsA)
- adults with active ankylosing spondylitis (AS)
- adults with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation
- people 4 years of age and older with active enthesitis-related arthritis (ERA)
- adults with moderate to severe hidradenitis suppurativa (HS)

IMPORTANT SAFETY INFORMATION

Do not use COSENTYX if you have had a severe allergic reaction to secukinumab or any of the other ingredients in COSENTYX. See the Medication Guide for a complete list of ingredients.

See additional Important Safety Information throughout brochure.

Click here for full [Prescribing Information](#), including [Medication Guide](#).

Visit [COSENTYX.com](https://www.cosentyx.com) for more information.



For adult use only.

REAL RESULTS. REAL RELIEF.

Most people who took COSENTYX[®] not only had less back pain and morning stiffness, they also saw improvement in their ability to move, and felt better overall.*†

*38% of people with nr-axSpA taking COSENTYX vs 19% taking placebo at 52 weeks.

†61% of people with AS taking COSENTYX vs 28% taking placebo at 16 weeks.

A similar percentage of people saw improvement at 5 years.

See page 5 for more info.

IMPORTANT SAFETY INFORMATION (cont)

What is the most important information I should know about COSENTYX?

COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as:

Infections

COSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have had serious infections while taking COSENTYX, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses. Some people have died from these infections.

- Your doctor should check you for TB before starting treatment with COSENTYX.
- If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with COSENTYX and during treatment with COSENTYX.

TAKE CONTROL WITH COSENTYX

Axial spondyloarthritis (axSpA) can not only be painful, but it can take a serious toll on your day-to-day. Living with back pain and morning stiffness can be challenging.

AxSpA includes two underdiagnosed conditions:

- Non-radiographic axial spondyloarthritis (nr-axSpA)
- Ankylosing spondylitis (AS)

In both conditions, inflammation in the spinal joints can cause chronic back pain, stiffness, fatigue, and reduced mobility. If left untreated, this inflammation can cause irreversible damage.

If you're struggling with back pain and reduced mobility, maybe it's time to take control. Read on to learn more. Then, ask your rheumatologist about COSENTYX. COSENTYX is the first medicine of its kind for nr-axSpA and AS to target IL-17A.

ABOUT COSENTYX	5
NR-AXSPA AND AS	6
RESULTS	8
DOSING	12
SUPPORT	14

See additional Important Safety Information throughout brochure. [Click here for full Prescribing Information, including Medication Guide.](#)

Visit COSENTYX.com for more information.

FIGHT AXIAL SPONDYLOARTHRITIS IN AN INNOVATIVE WAY

COSENTYX[®] **reduces symptoms** of axSpA (which includes the conditions AS or nr-axSpA), like **back pain and morning stiffness**.*

COSENTYX is designed to target and block IL-17A, which is one of the many proteins that may be involved in causing an overactive—or noisy—immune system.

COSENTYX helps “quiet the noise” in your immune system and can help you feel better.

COSENTYX is the most prescribed[†] FDA-approved IL-17A blocker.

*The relationship between how COSENTYX works in the body and how it affects your symptoms is unknown.



Patient portrayal.

SCAN THE CODE TO
LEARN MORE ABOUT HOW
COSENTYX WORKS



ABOUT COSENTYX

COSENTYX has been **studied extensively for over 17 years** across all indications. COSENTYX was approved by the FDA in 2015 to treat adults with moderate to severe plaque psoriasis. Then in 2016, it was approved by the FDA to treat active ankylosing spondylitis and active psoriatic arthritis. Most recently, in June 2020, it was approved by the FDA to treat another form of axSpA: nr-axSpA.



Read more to see why **more than 4 million** COSENTYX prescriptions have been filled in the United States.[†]

[†]Across all indications.

IMPORTANT SAFETY INFORMATION (cont)

- Your doctor should watch you closely for signs and symptoms of TB during treatment with COSENTYX. **Do not use COSENTYX if you have an active TB infection.**

Before starting COSENTYX, tell your doctor if you:

- are being treated for an infection
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- think you have an infection or have symptoms of an infection such as: fevers, sweats, or chills; muscle aches; cough; shortness of breath; blood in your phlegm; weight loss; warm, red, or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal

See additional Important Safety Information throughout brochure. [Click here for full Prescribing Information, including Medication Guide.](#)

Visit [COSENTYX.com](https://www.cosentyx.com) for more information.

UNDERSTANDING NR-AXSPA AND AS

AxSpA includes two underdiagnosed conditions: nr-axSpA and AS. In both conditions, inflammation in the spinal joints can cause chronic back pain, stiffness, fatigue, and reduced mobility. Nr-axSpA may be considered an early form of AS in some patients.

nr-axSpA

- Spinal damage will not appear on an X-ray, but may appear on an MRI
- Patients are more likely to be female (50%-60%)
- nr-axSpA may be considered an early form of AS in some patients

Up to 50% of nr-axSpA patients are at risk of developing AS.



AS

- Spinal damage will be seen on an X-ray
- Patients are more likely to be male
- Joint damage and spinal fusion



HEAR FROM REAL PATIENTS WHO ARE OUT MOVING AGAIN AT [COSENTYX.com](https://www.cosentyx.com)

IMPORTANT SAFETY INFORMATION (cont)

After starting COSENTYX, call your doctor right away if you have any signs of infection listed above. Do not use COSENTYX if you have any signs of infection unless you are instructed to by your doctor.

What are the possible side effects of COSENTYX?

COSENTYX may cause serious side effects, including:

Serious allergic reactions

Serious allergic reactions can occur. Get emergency medical help right away if you get any of the following symptoms: feeling faint; swelling of your face, eyelids, lips, mouth, tongue, or throat; trouble breathing or throat tightness; chest tightness; skin rash or hives (red, itchy bumps).

If you have a severe allergic reaction, do not give another injection of COSENTYX.

See additional Important Safety Information throughout brochure. Click here for full [Prescribing Information](#), including [Medication Guide](#).

Visit [COSENTYX.com](https://www.cosentyx.com) for more information.

MOVE AND FEEL BETTER

Most people who took COSENTYX® not only had less spinal pain and morning stiffness, they also saw improvement in their ability to move, and felt better overall.*†

RESULTS FAST. RELIEF THAT CAN LAST.

Managing nr-axSpA

1 YEAR	16 WEEKS
------------------	--------------------

Many people taking COSENTYX felt at least a **40% improvement** in overall symptoms at **1 year**.*† Many saw similar results **in as little as 16 weeks**.‡

Managing AS

16 WEEKS	5 YEARS
--------------------	-------------------


Twice as many people treated with COSENTYX achieved at least a **20% improvement** in overall symptoms **in as little as 16 weeks**.§ Many **continued to feel relief at 5 years**.†

*38% of people with nr-axSpA taking COSENTYX vs 19% taking placebo.

†At 1 year, patients and doctors were told which medication was being used, which may affect results.

‡41% of people with nr-axSpA taking COSENTYX vs 28% taking placebo.

§61% of people with AS taking COSENTYX vs 28% taking placebo.



Mark was compensated for his time. Individual results may vary.

"I can do fun things I wasn't able to do before."

MARK ACTUAL PATIENT

IMPORTANT SAFETY INFORMATION (cont)

Inflammatory bowel disease

New cases of inflammatory bowel disease or "flare-ups" can happen with COSENTYX, and can sometimes be serious. If you have inflammatory bowel disease (ulcerative colitis or Crohn's disease), tell your doctor if you have worsening disease symptoms during treatment with COSENTYX or develop new symptoms of stomach pain or diarrhea.

Severe skin reactions that look like eczema

can happen during treatment with COSENTYX from days to months after your first dose and can sometimes lead to hospitalization. Your doctor may temporarily stop treatment with COSENTYX if you develop severe skin reactions.

See additional Important Safety Information throughout brochure. Click here for full [Prescribing Information](#), including [Medication Guide](#).

Visit COSENTYX.com for more information.

COSENTYX CAN HELP YOU FEEL BETTER

When people taking COSENTYX® were given a survey by their doctors that measured how well their treatment was working,* the overall results showed improvements in some or all of the following symptoms of nr-axSpA and AS.



TOTAL SPINAL PAIN



MORNING STIFFNESS



FATIGUE



TENDERNESS (ENTHESITIS)



JOINT PAIN AND SWELLING

Make sure to **talk to your rheumatologist about COSENTYX** and what you can expect when you get started.

*Bath Ankylosing Spondylitis Disease Activity Index.

IMPORTANT SAFETY INFORMATION (cont)

Tell your doctor if you have any of the following signs or symptoms: redness or rash; itching; small bumps or patches; your skin is dry or feels like leather; blisters on the hands or feet that ooze or become crusty or skin peeling.

The most common side effects of COSENTYX include: cold symptoms, diarrhea, and upper respiratory tract infections.



Garth was compensated for his time. Individual results may vary.

Need help getting the conversation started with your doctor? [Click here](#) to use our Doctor Conversation Starter.

IMPORTANT SAFETY INFORMATION (cont)

These are not all of the possible side effects of COSENTYX. Call your doctor for medical advice about side effects.

Before using COSENTYX, tell your doctor if you:

- have any of the conditions or symptoms listed above for infections.
- have inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- are allergic to latex. The needle cap on the COSENTYX Sensoready® pen, and 150 mg/mL and 75 mg/0.5 mL prefilled syringes contains latex.
- have recently received or are scheduled to receive an immunization (vaccine). People who take COSENTYX **should not** receive live vaccines. Children should be brought up to date with all vaccines before starting COSENTYX.
- have any other medical conditions and all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine.

See additional Important Safety Information throughout brochure. [Click here](#) for full [Prescribing Information](#), including [Medication Guide](#).

Visit COSENTYX.com for more information.



GET COMFORTABLE WITH COSENTYX®

COSENTYX is taken by injection, either with the Sensoready® Pen or a prefilled syringe. Work with your rheumatologist to decide which device is best for you.*

THE SENSOREADY® PEN IS EASY TO USE

The Sensoready Pen is designed to be easy-to-use and comfortable. People in a clinical trial who used the Sensoready Pen found it easy to use.

Very few people in clinical trials (2.6%) experienced injection-site reactions with COSENTYX.†

COSENTYX IS A CONVENIENT, ONCE-A-MONTH DOSE*

The recommended dose of COSENTYX for nr-axSpA and AS is 150 mg. If you continue to have AS symptoms, your rheumatologist may prescribe 300 mg (taken as two 150 mg injections).

*Your rheumatologist may prescribe 5 weekly doses to get you started.

†Results from nr-axSpA clinical trial at week 52.

IMPORTANT SAFETY INFORMATION (cont)

- are pregnant or plan to become pregnant. It is not known if COSENTYX can harm your unborn baby. You and your doctor should decide if you will use COSENTYX.
- are breastfeeding or plan to breastfeed. It is not known if COSENTYX passes into your breast milk.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.



Designed for comfort, the Sensoready Pen helps hide the needle so you don't even have to see it.

INJECTION RESOURCES



For added support, a COSENTYX® Connect team member is available at **1-844-COSENTYX (1-844-267-3689)**

You can also view our injection resources and demonstration videos at **COSENTYX.com/injectiontraining**

See additional Important Safety Information throughout brochure. Click here for full [Prescribing Information](#), including [Medication Guide](#).

Visit COSENTYX.com for more information.

REAL SUPPORT AND PERSONAL SOLUTIONS

COSENTYX® Connect is a free personal support program that's tailored to your needs right from the start.

For those who are taking COSENTYX®, here's what you will get once you sign up:

- **A COSENTYX® Connect Team Member**
- **Pay as little as \$0 co-pay* if commercially insured and otherwise eligible**
- **If eligible, you may get up to 2 years of COSENTYX for free with the Covered Until You're Covered Program† if your insurance coverage is denied while coverage is pursued**
- **Get help navigating insurance coverage**
- **Personalized resources via mail, email, and text updates**
- **Injection resources**

Call us to find out more at **1-844-COSENTYX (1-844-267-3689)** or visit **COSENTYX.com** for more information.

*Limitations apply. Valid only for those with private insurance. Program provides up to \$16,000 annually for the cost of COSENTYX and up to \$150 per infusion (up to \$1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.

†The **Covered Until You're Covered Program** is available for COSENTYX® (secukinumab) subcutaneous injection only. Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides COSENTYX for free to eligible patients for up to two years, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

See additional Important Safety Information throughout brochure. [Click here for full Prescribing Information, including Medication Guide.](#)

Visit COSENTYX.com for more information.

GETTING COSENTYX[®] COVERED

A COSENTYX[®] Connect team member, will work with you and your healthcare provider to help get your COSENTYX prescription approved. Go to [COSENTYX.com/how-to-get-cosentyx](https://www.cosentyx.com/how-to-get-cosentyx) for a full walk-through of the steps for getting COSENTYX.

GETTING COSENTYX DELIVERED

COSENTYX is sent to you from a specialty pharmacy since it's a biologic drug, which means it requires special handling and must be refrigerated.

GETTING FINANCIAL ASSISTANCE

If commercially insured you may be eligible to pay as little as **\$0 co-pay***. 94%¹ of eligible patients who used the program in 2022 paid \$0 out of pocket.

NEED HELP NAVIGATING YOUR COVERAGE?

In the unlikely event that your coverage is denied, we'll do everything we can to help. Learn more about our Covered Until You're Covered Program.[†] If eligible, the program offers up to 2 years of COSENTYX for free if your coverage isn't initially approved while coverage is pursued. For more coverage assistance, head to [COSENTYX.com/how-to-get-cosentyx](https://www.cosentyx.com/how-to-get-cosentyx).



"My experience went really smoothly, they really walk you through all the steps you need to take."

WENDY ACTUAL PATIENT

Wendy was compensated for her time. Individual results may vary.

If you can't afford your medicine, Novartis may be able to help. Please visit [COSENTYX.com/cost](https://www.cosentyx.com/cost) or call **1-844-COSENTYX (1-844-267-3689)** to learn more.

*Limitations apply. Valid only for those with private insurance. Program provides up to \$16,000 annually for the cost of COSENTYX and up to \$150 per infusion (up to \$1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.

[†]The **Covered Until You're Covered Program** is available for COSENTYX[®] (secukinumab) subcutaneous injection only. Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides COSENTYX for free to eligible patients for up to two years, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

See additional Important Safety Information throughout brochure. Click here for full [Prescribing Information](#), including [Medication Guide](#).

Visit [COSENTYX.com](https://www.cosentyx.com) for more information.

**WATCH
ME**



For adult use only.

**ASK YOUR RHEUMATOLOGIST
ABOUT COSENTYX[®] TODAY**



Visit **COSENTYX.com**



Follow us on X **@COSENTYXUSOnly**



Like us on Facebook at **@COSENTYX (secukinumab)**



See real stories from people taking COSENTYX
on Instagram at **@cosentyxsecukinumab**

See Important Safety Information throughout brochure.
Click here for full Prescribing Information, including Medication Guide.

Reference: 1. Data on File, Cosentyx NPS Co-pay Data. Novartis Pharmaceuticals Corp; March 2023.



Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2024 Novartis

10/24

FA-11247217